In the Phase 3 LEAP-012 trial, LENVIMA plus KEYTRUDA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone

LENVIMA Plus KEYTRUDA in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcin